The Technical Analyst
Spectrum Pharmaceuticals [SPPI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Spectrum Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.49% $1.025
America/New_York / 31 jul 2023 @ 15:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 210.38 mill |
| EPS: | -0.360 |
| P/E: | -2.85 |
| Earnings Date: | Nov 07, 2023 |
| SharesOutstanding: | 205.25 mill |
| Avg Daily Volume: | 1.642 mill |
| RATING 2023-07-31 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.85 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.48x |
| Company: PE -2.85 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.979 - 1.081 ( +/- 4.95%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
| 2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
| 2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
| 2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
| 2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -27.00 |
| Last 97 transactions |
| Buy: 24 888 642 | Sell: 15 180 768 |
Forecast:
01:40 - $1.107
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.025 (-0.49% ) |
| Volume | 4.85 mill |
| Avg. Vol. | 1.642 mill |
| % of Avg. Vol | 295.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SPPI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SPPI
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Latest Press Releases
2023-11-13 01:15:00 - Press Release
Basilea Announces Acquisition Of Fosmanogepix, A Phase-3-ready Broad-spectrum Antifungal
Ad hoc announcement pursuant to art. 53 lr allschwil, switzerland, november 13, 2023 basilea pharmaceutica ltd, allschwil (six: bsln), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with amplyx pharmaceuticals, inc., an affiliate of pfizer inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.
2023-10-02 04:00:00 - Press Release
Pneumagen Announces Successful Clinical Proof Of Concept For Its Broad-spectrum Antiviral Neumifil In Phase 2 Influenza Human Challenge Study
St andrews, uk – 2nd october 2023 - pneumagen, a clinical stage biotech company developing neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (rtis), today announced positive results from its phase 2, proof of concept, controlled human infection model (chim) study where patients were challenged with influenza virus following administration of neumifil.
2023-07-27 18:30:00 - Press Release
Osivax Announces Publication In The Lancet Infectious Diseases Of Phase 2a Data For Broad-spectrum Influenza Vaccine Candidate, Ovx836
Lyon, france--(business wire)--osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the lancet infectious diseases published results from the company's ovx836-003 study under the title, “immunogenicity, safety and preliminary efficacy evaluation of ovx836, a nucleoprotein-based universal influenza a vaccine candidate: randomised, double-blind placebo-controlled, phase 2a trial.” the research.
2023-07-20 07:00:00 - Press Release
Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “for” Proposed Transaction With Assertio Holdings, Inc.
Boston--(business wire)--spectrum pharmaceuticals, inc. (nasdaqgs: sppi) (“spectrum” or the “company”) announced today that the leading independent proxy advisory firms, institutional shareholder services, inc. (“iss”) and glass lewis & co. (“glass lewis”), have each recommended that spectrum stockholders vote “for” the proposal to adopt the agreement and plan of merger (“merger agreement”, and such proposal, the “merger proposal”) at the upcoming special meeting of stockholders (the “speci.
2023-06-30 15:35:00 - Press Release
Spectrum Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Spectrum Pharmaceuticals, Inc. - Sppi
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of spectrum pharmaceuticals, inc. (nasdaqgs: sppi) to assertio holdings, inc. (nasdaqcm: asrt). under the terms of the proposed transaction, shareholders of spectrum will receive, for each share of spectrum that they own, 0.1783 shares of assertio and one contingent value right for the right to receive $0.10 paya.
Latest News
2023-11-28 09:19:53 - Proactive Investors
NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels from the two formulations used in the study, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.
2023-08-21 08:16:23 - Proactive Investors
NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collaborator and drug sponsor, Karveer Meditech, about 26 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1a Single-Ascending-Dose (SAD) have already completed the study.
2023-06-22 19:46:02 - Seeking Alpha
Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a $3B domestic market. The combined companies of Assertio and Spectrum are estimated to provide a return of 4x.
2023-05-09 09:56:57 - Zacks Investment Research
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
2023-05-08 15:18:47 - PennyStocks
7 Hot Penny Stocks Under $1.10 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-05-05 13:09:12 - PennyStocks
Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now
2023-04-25 11:51:48 - Proactive Investors
Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium
Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning. The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.
2023-04-25 08:27:55 - InvestorPlace
Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.
2023-04-03 22:49:50 - 24/7 Wall Street
10 Best-Performing Penny Stocks in the Health Care Sector
2023-03-22 13:07:03 - Seeking Alpha
Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Thomas Riga - President and Chief Executive Officer Michael Grabow - Executive Vice President and Chief Financial Officer Nora Brennan - Executive Vice President and Chief Financial Officer Erin Miller - Senior Vice President Sales and Marketing Conference Call Participants Maury Raycroft - Jefferies Edward White - H.C. Wainwright Reni Bennett Benjamin - JMP Securities Prakhar Agarwal - Cantor Fitzgerald Operator Good day and thank you for standing by.